What is HC Wainwright’s Estimate for DBVT FY2024 Earnings?

DBV Technologies S.A. (NASDAQ:DBVT) – Equities researchers at HC Wainwright upped their FY2024 EPS estimates for DBV Technologies in a research note issued to investors on Wednesday, October 23rd. HC Wainwright analyst A. Fein now forecasts that the company will earn ($1.41) per share for the year, up from their prior estimate of ($1.43). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.50) EPS.

Several other equities analysts have also weighed in on the stock. StockNews.com started coverage on shares of DBV Technologies in a research report on Monday. They set a “hold” rating on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a research report on Tuesday, September 24th.

DBV Technologies Stock Performance

NASDAQ:DBVT opened at $0.84 on Friday. The company has a market capitalization of $80.81 million, a P/E ratio of -1.00 and a beta of 0.67. The stock’s 50 day moving average price is $0.78 and its 200 day moving average price is $0.96. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $2.28.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.08). The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period in the previous year, the company earned ($0.26) earnings per share.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. grew its position in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.